Safety, tolerability, and pharmacokinetics of SMT C1100, a 2‐arylbenzoxazole utrophin modulator, following single‐ and multiple‐dose administration to healthy male adult volunteers
Open Access
- 4 February 2015
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 55 (6), 698-707
- https://doi.org/10.1002/jcph.468
Abstract
SMT C1100 is a small molecule utrophin modulator in development to treat Duchenne muscular dystrophy. This study evaluated the safety, tolerability, and pharmacokinetics of SMT C1100 in healthy volunteers. This double-blind, placebo-controlled Phase 1 study comprised: Part 1, an escalating, single-dose with/without fasting involving 50 mg/kg, 100 mg/kg, 200 mg/kg, and 400 mg/kg doses; and Part 2, a multiple 10 day dose evaluation involving 100 mg/kg bid and 200 mg/kg bid doses. Adverse events were recorded. SMT C1100 was absorbed rapidly following single and multiple oral doses, with median tmax attained within 2–3.5 hour across all doses. Considerable variability of pharmacokinetic parameters was noted among subjects. Following single doses, systemic exposure increased in a sub-proportional manner, with the 8.0-fold dose increment resulting in 2.7- and 2.4-fold increases in AUC0-∞ and Cmax, respectively. AUC0-∞ and Cmax were estimated as 4.2- and 4.8-fold greater, respectively, following food. Systemic exposure reduced upon repeat dosing with steady-state concentrations achieved within 3–5 days of multiple bid dosing. No serious or severe adverse events were reported. SMT C1100 was safe and well tolerated with plasma concentrations achieved sufficient to cause a 50% increase in concentrations of utrophin in cells in vitro.Keywords
This publication has 11 references indexed in Scilit:
- Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapies.2013
- Daily Treatment with SMTC1100, a Novel Small Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in the mdx MousePLOS ONE, 2011
- Discovery of 2-Arylbenzoxazoles as Upregulators of Utrophin Production for the Treatment of Duchenne Muscular DystrophyJournal of Medicinal Chemistry, 2011
- Nonmolecular treatment for muscular dystrophiesCurrent Opinion in Neurology, 2005
- Advances in Duchenne muscular dystrophy gene therapyNature Reviews Genetics, 2003
- Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin/NFAT signalingProceedings of the National Academy of Sciences of the United States of America, 2003
- Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression systemHuman Molecular Genetics, 2002
- Expression of full-length utrophin prevents muscular dystrophy in mdx miceNature Medicine, 1998
- Pharmacokinetic analysis of mizolastine in healthy young volunteers after single oral and intravenous doses: noncompartmental approach and compartmental modeling.Journal of Pharmacokinetics and Biopharmaceutics, 1997
- Molecular and Functional Analysis of the Utrophin PromoterNucleic Acids Research, 1996